Press Releases

Latest Press Releases

Press Releases
18 August 2022

For UK medical/trade/consumer media only: The National Institute for Health and Care Excellence issues positive Appraisal Consultation Document for Eisai’s Kisplyx® (lenvatinib) in combination with MSD’s Keytruda® (pembrolizumab) for first-line treatment of intermediate and poor risk advanced renal cell carcinoma

pdf - 257 KB
Download
Press Releases
13 June 2022

For UK medical/trade/consumer media only: Scottish Medicines Consortium recommends combination of Kisplyx® (lenvatinib) plus Keytruda® (pembrolizumab) for first-line treatment of advanced renal cell carcinoma

pdf - 198 KB
Download
Press Releases
15 October 2021

For European medical/trade media only: Eisai and Merck receive simultaneous positive CHMP Opinions for Lenvima® (lenvatinib) plus Keytruda® (pembrolizumab) in advanced endometrial carcinoma and Kisplyx® (lenvatinib) plus Keytruda® (pembrolizumab) in advanced renal cell carcinoma

pdf - 178 KB
Download